# Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

Study · id `cardio:ct-nct06701825` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06701825](<https://clinicaltrials.gov/study/NCT06701825>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06701825

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 114 participants.

## Technical summary

Registry record NCT06701825. Randomized; single masking; primary purpose treatment. Start 2025-06-02 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 114 participants (planned count; ClinicalTrials.gov record NCT06701825, source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)
- Started: 2025-06-02 (actual) (ClinicalTrials.gov record NCT06701825, source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)
- Primary completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT06701825, source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06701825, source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06701825, source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06701825-2025-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
- Acronym: TRANSPGx
- Condition: Kidney Disease, Chronic
- Condition: Transplant Recipient (Kidney)
- Condition: Immunosuppression
- Intervention (Drug): Tacrolimus
- Intervention (Drug): Tacrolimus
- Lead sponsor: Instituto de Investigación Hospital Universitario La Paz
- Lead sponsor class: OTHER
- Collaborator: Instituto de Salud Carlos III
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Instituto de Investigación Hospital Universitario La Paz (`cardio:org-instituto-de-investigacion-hospital-universitario-la-paz`)
- Registry lists this organization as a collaborator: Instituto de Salud Carlos III (`cardio:org-instituto-de-salud-carlos-iii`)

## Provenance

Content hash: c49cfa8ff5072bbda8696fc175d16e9530e65ff21fb286d9adcabd54fc65329b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
